以及亚胺培南联合替加环素、利福布丁和阿维巴坦对 . 的细胞内活性。
and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against .
机构信息
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France
出版信息
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01915-18. Print 2019 Apr.
Abstract
infections are difficult to treat because of their resistance to many antibiotics. , tedizolid combined with imipenem displayed a moderate synergistic effect (fractional inhibitory concentration index, 0.41) but no bactericidal activity. Intracellularly, tedizolid 2 μg/ml (half of the MIC), corresponding to the peak serum concentration, increased the efficacy of imipenem at 8 and 32 μg/ml. Addition of avibactam and rifabutin, alone or in combination, improved the activity of the imipenem-tedizolid combination.
摘要
这些感染很难治疗，因为它们对许多抗生素具有耐药性。替加环素与亚胺培南联合显示出适度的协同作用（抑菌浓度指数，0.41），但没有杀菌活性。在细胞内，替加环素 2μg/ml（MIC 的一半），相当于血清峰浓度，增加了 8μg/ml 和 32μg/ml 亚胺培南的疗效。阿维巴坦和利福布丁单独或联合使用可提高亚胺培南-替加环素联合用药的活性。
相似文献
1
and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against .以及亚胺培南联合替加环素、利福布丁和阿维巴坦对 . 的细胞内活性。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01915-18. Print 2019 Apr.
2
and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.并评估亚胺培南联合利福布汀和阿维巴坦对脓肿分枝杆菌的胞内活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00623-18. Print 2018 Aug.
3
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.利福布汀与克拉霉素、亚胺培南和替加环素联合应用对复合体的协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.
4
In vitro activity of tedizolid against the Mycobacterium abscessus complex.替加环素对脓肿分枝杆菌复合群的体外活性。
Diagn Microbiol Infect Dis. 2018 Mar;90(3):186-189. doi: 10.1016/j.diagmicrobio.2017.11.001. Epub 2017 Nov 10.
5
Evolution toward extremely high imipenem resistance in outbreak strains.在暴发菌株中向极高的亚胺培南耐药性进化。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0067324. doi: 10.1128/aac.00673-24. Epub 2024 Sep 10.
6
Inhibition of the β-Lactamase Bla by Avibactam Improves the and Efficacy of Imipenem against Mycobacterium abscessus.阿维巴坦对β-内酰胺酶Bla的抑制作用提高了亚胺培南对脓肿分枝杆菌的活性和疗效。
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02440-16. Print 2017 Apr.
7
Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.利福布丁与一线抗分枝杆菌抗生素克拉霉素和替加环素协同作用并具有杀菌作用，提示这是一种有效的治疗组合。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00283-18. Print 2018 Aug.
8
Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.阿莫西林联合亚胺培南-西司他丁钠对脓肿分枝杆菌的作用。
Sci Rep. 2020 Jan 27;10(1):928. doi: 10.1038/s41598-020-57844-8.
9
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex .双联β-内酰胺组合对脓肿分枝杆菌复合体高度有效。
mBio. 2019 Feb 12;10(1):e02895-18. doi: 10.1128/mBio.02895-18.
10
Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem.雷巴他定对脓肿分枝杆菌 BlaMab β-内酰胺酶的抑制作用对亚胺培南体外和细胞内疗效的影响。
J Antimicrob Chemother. 2020 Feb 1;75(2):379-383. doi: 10.1093/jac/dkz433.
引用本文的文献
1
The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination against in a mouse model of infection.在小鼠感染模型中，添加阿莫西林可提高亚胺培南-阿维巴坦联合用药对[具体病原体未给出]的疗效。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0053425. doi: 10.1128/aac.00534-25. Epub 2025 Jul 21.
2
Novel C5α-substituted carbapenems enhance killing via selective target binding and reduced hydrolysis by Bla.新型C5α取代碳青霉烯类药物通过选择性靶点结合和降低Bla水解作用增强杀菌效果。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017025. doi: 10.1128/aac.00170-25. Epub 2025 Jun 17.
3
Synthesis and anti-mycobacterial activity of novel medium-chain β-lactone derivatives: a multi-target strategy to combat .新型中链β-内酯衍生物的合成及其抗分枝杆菌活性：一种对抗……的多靶点策略
RSC Med Chem. 2025 Apr 25. doi: 10.1039/d5md00102a.
4
Durlobactam in combination with β-lactams to combat .杜洛巴坦与β-内酰胺类联合使用以对抗……
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0117424. doi: 10.1128/aac.01174-24. Epub 2024 Dec 23.
5
Evolution toward extremely high imipenem resistance in outbreak strains.在暴发菌株中向极高的亚胺培南耐药性进化。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0067324. doi: 10.1128/aac.00673-24. Epub 2024 Sep 10.
6
Evolution towards extremely high β-lactam resistance in outbreak strains.暴发菌株中对β-内酰胺类抗生素的耐药性向极高水平演变。
bioRxiv. 2024 May 9:2024.05.08.593223. doi: 10.1101/2024.05.08.593223.
7
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.探索[具体对象]中的抗生素耐药机制以改进治疗方法。 （你提供的原文“Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.”中“in for”之间缺少具体内容，我根据语境补充了“[具体对象]”，你可根据实际情况调整）
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
8
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
9
Repurposing miconazole and tamoxifen for the treatment of Mycobacterium abscessus complex infections through in silico chemogenomics approach.通过计算机辅助化学生物基因组学方法，重新利用咪康唑和他莫昔芬治疗脓肿分枝杆菌复合体感染。
World J Microbiol Biotechnol. 2023 Aug 9;39(10):273. doi: 10.1007/s11274-023-03718-w.
10
Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.氯法齐明作为对照药物用于评估实验性治疗药物在小鼠肺部 M. abscessus 感染中的临床前疗效。
Tuberculosis (Edinb). 2022 Dec;137:102268. doi: 10.1016/j.tube.2022.102268. Epub 2022 Oct 4.
本文引用的文献
1
and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.并评估亚胺培南联合利福布汀和阿维巴坦对脓肿分枝杆菌的胞内活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00623-18. Print 2018 Aug.
2
In vitro activity of tedizolid against the Mycobacterium abscessus complex.替加环素对脓肿分枝杆菌复合群的体外活性。
Diagn Microbiol Infect Dis. 2018 Mar;90(3):186-189. doi: 10.1016/j.diagmicrobio.2017.11.001. Epub 2017 Nov 10.
3
Epidemiology and Predictors of NTM Pulmonary Infection in Taiwan - a Retrospective, Five-Year Multicenter Study.台湾地区非结核分枝杆菌肺部感染的流行病学和预测因素：一项回顾性、五年多中心研究。
Sci Rep. 2017 Nov 24;7(1):16300. doi: 10.1038/s41598-017-16559-z.
4
Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of Mycobacterium abscessus complex disease: A retrospective analysis for two major hospitals in a subtropical region of Japan.非结核分枝杆菌肺病的致病菌种及脓肿分枝杆菌复合群疾病临床特征的比较研究：日本亚热带地区两家主要医院的回顾性分析
PLoS One. 2017 Oct 23;12(10):e0186826. doi: 10.1371/journal.pone.0186826. eCollection 2017.
5
Rifabutin Is Active against Mycobacterium abscessus Complex.利福布汀对脓肿分枝杆菌复合群有活性。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
6
Inhibition of the β-Lactamase Bla by Avibactam Improves the and Efficacy of Imipenem against Mycobacterium abscessus.阿维巴坦对β-内酰胺酶Bla的抑制作用提高了亚胺培南对脓肿分枝杆菌的活性和疗效。
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02440-16. Print 2017 Apr.
7
Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate.阿维巴坦和克拉维酸对分枝杆菌β-内酰胺酶的抑制作用。
J Antimicrob Chemother. 2017 Apr 1;72(4):1081-1088. doi: 10.1093/jac/dkw546.
8
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.头孢他啶/阿维巴坦聚焦：耐多药革兰氏阴性菌感染的新选择。
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
9
Bactericidal and intracellular activity of β-lactams against Mycobacterium abscessus.β-内酰胺类药物对脓肿分枝杆菌的杀菌及胞内活性
J Antimicrob Chemother. 2016 Jun;71(6):1556-63. doi: 10.1093/jac/dkw022. Epub 2016 Feb 29.
10
Treatment of Mycobacterium abscessus Infection.脓肿分枝杆菌感染的治疗
Emerg Infect Dis. 2016 Mar;22(3):511-4. doi: 10.3201/eid2203.150828.
Zotero 插件